Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting
- PMID: 22994166
- PMCID: PMC3477946
- DOI: 10.2105/AJPH.2012.300659
Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting
Abstract
Objectives: We evaluated an intervention designed to identify patients at risk for hepatitis C virus (HCV) through a risk screener used by primary care providers.
Methods: A clinical reminder sticker prompted physicians at 3 urban clinics to screen patients for 12 risk factors and order HCV testing if any risks were present. Risk factor data were collected from the sticker; demographic and testing data were extracted from electronic medical records. We used the t test, χ(2) test, and rank-sum test to compare patients who had and had not been screened and developed an analytic model to identify the incremental value of each element of the screener.
Results: Among screened patients, 27.8% (n = 902) were identified as having at least 1 risk factor. Of screened patients with risk factors, 55.4% (n = 500) were tested for HCV. Our analysis showed that 7 elements (injection drug use, intranasal drug use, elevated alanine aminotransferase, transfusions before 1992, ≥ 20 lifetime sex partners, maternal HCV, existing liver disease) accounted for all HCV infections identified.
Conclusions: A brief risk screener with a paper-based clinical reminder was effective in increasing HCV testing in a primary care setting.
Figures
Similar articles
-
Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk.Dig Liver Dis. 2012 Jun;44(6):497-503. doi: 10.1016/j.dld.2011.12.014. Epub 2012 Feb 18. Dig Liver Dis. 2012. PMID: 22342471
-
Impact of electronic reminder systems on hepatitis C screening in primary care.J Viral Hepat. 2018 Aug;25(8):939-944. doi: 10.1111/jvh.12885. Epub 2018 Mar 30. J Viral Hepat. 2018. PMID: 29478306
-
The disposition of hepatitis C antibody-positive patients in an urban hospital.J Viral Hepat. 2009 Nov;16(11):814-21. doi: 10.1111/j.1365-2893.2009.01137.x. J Viral Hepat. 2009. PMID: 19842281
-
Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios.J Hepatol. 2015 Jun;62(6):1256-64. doi: 10.1016/j.jhep.2015.01.011. Epub 2015 Jan 21. J Hepatol. 2015. PMID: 25617500
-
Hepatitis C virus: Prevention, screening, and interpretation of assays.Cleve Clin J Med. 2010 Sep;77(9):616-26. doi: 10.3949/ccjm.77a.09162. Cleve Clin J Med. 2010. PMID: 20810872 Review.
Cited by
-
Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study.Hepatology. 2017 Jan;65(1):44-53. doi: 10.1002/hep.28880. Epub 2016 Nov 25. Hepatology. 2017. PMID: 27770543 Free PMC article.
-
Screening at a Federally Qualified Health Center in the Midwest for Hepatitis C Among People Who Inject Drugs, 2019-2020.Prev Chronic Dis. 2021 Jul 15;18:E69. doi: 10.5888/pcd18.200604. Prev Chronic Dis. 2021. PMID: 34264813 Free PMC article.
-
Hepatitis C Screening in People With Human Immunodeficiency Virus: Lessons Learned From Syphilis Screening.Open Forum Infect Dis. 2016 Feb 12;3(1):ofv215. doi: 10.1093/ofid/ofv215. eCollection 2016 Jan. Open Forum Infect Dis. 2016. PMID: 26885544 Free PMC article.
-
Evaluation of a strategy for identification of hepatitis C virus carriers in outpatient and emergency units: contribution to the microelimination of hepatitis C in Brazil.Braz J Infect Dis. 2021 Mar-Apr;25(2):101546. doi: 10.1016/j.bjid.2021.101546. Epub 2021 Feb 23. Braz J Infect Dis. 2021. PMID: 33636108 Free PMC article.
-
Recommendations for the management of hepatitis C virus infection among people who inject drugs.Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17. Int J Drug Policy. 2015. PMID: 26282715 Free PMC article.
References
-
- Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WK, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–714 - PubMed
-
- Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection. Ann Intern Med. 2010;153(4):231–239 - PubMed
-
- Ly K, Xing J, Klevens M, Jiles R, Ward J, Holmberg S. The growing burden of mortality from viral hepatitis in the US, 1999–2007. Paper presented at: annual meeting of the American Association for the Study of Liver Diseases, November 2011, San Francisco, CA.
-
- Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50(6):1750–1755 - PubMed
-
- Kwo PY, Lawitz EJ, McCone Jet al.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705–716 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical